Cantor: Time To Buy StemCells
In a report published Friday, Cantor Fitzgerald analysts initiated coverage of StemCells Inc (NASDAQ: STEM) with a Buy rating and a price target of $2.
StemCells is a biopharmaceutical company focused on researching, developing and commercializing cell based technologies to repair or support organ function.
The company is uniquely positioned to enter two areas of spinal repair and dry-AM D geographic atrophy, with no therapeutic options at present. "The two segments have few competitive players and no approved therapies," the analysts mentioned.
"While the cell therapy space has been plagued with efficacy failures, we think StemCells' early data across multiple conditions in the central nervous system are compelling," the analysts stated.
StemCells has reported positive data from its Phase I/II thoracic (mid-back) spine data. In the report Cantor Fitzgerald noted, "We think this is under-appreciated by Wall Street and we think it bodes well for the company's Phase 2 trial in cervical (neck) spine (the Pathway trial), which commenced in October 2014."
Early data from StemCells' Phase I/II clinical trial for opthalmology indications is promising and the final data from these trials is expected in June 2015. "Building upon the Phase I/II data, StemCells is opening sites for its 63-patient Phase II controlled trial (the Radiant trial) in dry-AMD/ GA, with a 12-month primary endpoint," the analysts wrote.
Latest Ratings for STEM
|May 2016||Maxim Group||Downgrades||Buy||Hold|
|Apr 2016||Rodman & Renshaw||Assumes||Buy|
|Nov 2015||H.C. Wainwright||Assumes||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.